Sartorius Stedim Biotech dividend and valuation
Valuation
Sartorius Stedim Biotech paid €0.69 per share in dividends over the last 12 months (yield 0.3%). Last ex-dividend date: March 31, 2026. The P/E ratio is 67.0. The average price target of 13 analysts is €250.00.
Data as of November 16, 2026
Sartorius Stedim Biotech compared with similar companies
Sartorius Stedim Biotech's P/E (trailing 12 months): 67.0, +59% against the median of a group of 10 similar companies (42.2).
| Metric | Sartorius Stedim Biotech | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 67.0 | 42.2 | 34.3 – 55.5 | High |
| Forward P/E | 36.8 | 23.3 | 18.0 – 30.0 | High |
| EV/EBITDA | 28.6 | 16.9 | 13.7 – 21.9 | High |
| Price/book | 4.97 | 4.73 | 3.04 – 6.67 | Middle |
| Price/sales | 7.09 | 3.52 | 2.80 – 5.42 | High |
| Gross margin | 44.6% | 56.0% | 43.8% – 63.3% | Middle |
| Operating margin | 19.2% | 16.4% | 13.3% – 21.9% | Middle |
| Net margin | 10.6% | 8.5% | 6.0% – 12.0% | Middle |
| ROE | 7.7% | 7.9% | 7.2% – 18.6% | Middle |
| Debt/equity | 0.53 | 0.38 | 0.28 – 0.87 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Sartorius Stedim Biotech: valuation over time
On the latest fiscal year's earnings (2025), Sartorius Stedim Biotech's P/E today is 82.2, above the median of its last 10 fiscal years (64.6; between 31.8 and 107.3 from 2016 to 2025). Relative to earnings, the stock costs more than it used to. The dividend yield (0.3%) is in line with the median of the last 10 fiscal years (0.3%).
| Fiscal year | Price at year end | Earnings per share | P/E | Dividend per share | Yield |
|---|---|---|---|---|---|
| 2025 | €210.00 | €2.73 | 76.9 | €0.69 | 0.3% |
| 2024 | €188.70 | €1.81 | 104.3 | €0.69 | 0.4% |
| 2023 | €239.50 | €3.37 | 71.1 | €0.69 | 0.3% |
| 2022 | €302.50 | €9.51 | 31.8 | €1.44 | 0.5% |
| 2021 | €482.40 | €4.50 | 107.3 | €1.26 | 0.3% |
| 2020 | €291.20 | €3.64 | 80.0 | €0.68 | 0.2% |
| 2019 | €147.70 | €2.54 | 58.1 | €0.34 | 0.2% |
| 2018 | €87.35 | €2.26 | 38.7 | €0.57 | 0.7% |
| 2017 | €60.29 | €1.75 | 34.5 | €0.46 | 0.8% |
| 2016 | €59.97 | €1.67 | 36.0 | €0.42 | 0.7% |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only); yield = dividend per share for the year divided by the same price. Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above; today's yield uses dividends over the last 12 months.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- €21.72B
- Enterprise value
- €23.9B
- PEG
- 1.61
- EV/revenue
- 7.81
Profitability and growth
- ROA
- 4.6%
- ROIC
- 5.5%
- Revenue growth (year over year)
- 8.0%
- Earnings growth (year over year)
- 48.5%
Financial health
- Total cash
- €172M
- Total debt
- €2.31B
- Current ratio
- 1.22
- Quick ratio
- 0.46
- Altman Z-Score
- 4.15
- Piotroski F-Score
- 6.00
Dividends
- Annual dividend per share
- €0.69
- Dividend yield
- 0.3%
- Payout ratio
- 20.7%
- Ex-dividend date
- March 31, 2026
Analysts and estimates
- Average price target
- €250.00
- Median price target
- €250.00
- High price target
- €281.00
- Low price target
- €218.00
- Analysts with a price target
- 13
- Consensus
- Buy
- Forward EPS
- €6.06
- EPS estimate, current year
- €4.98
Shares and trading
- Beta
- 1.18
- Average volume
- 92.8K
- Shares outstanding
- 97.31M
- Float
- 27.78M
- Institutional ownership
- 12.3%
- Insider ownership
- 71.5%
